Plasma Osteoprotegerin Predicts Adverse Cardiovascular Events in Stable Coronary Artery Disease: the PEACE Trial

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Jun 30

PMID 37388640

Authors

Teng Ma

Jian Zhao

Yechao Yan

Junying Liu

Jie Zang

Yaqi Zhang

Kun Ruan

Hong Xu

Wan He

Affiliations

Soon will be listed here.

Abstract

Background: Osteoprotegerin (OPG) is a secretory glycoprotein and participates in the progression of atherosclerotic lesions. We aim to explore the relationship between OPG and the prognosis of coronary artery disease (CAD).

Methods: Plasma OPG concentrations were measured in 3,766 patients with stable CAD enrolled in the PEACE trial. The PEACE trial (NCT00000558) group followed up the patients and examined their future clinical outcomes.

Results: In summary, 208 (5.5%) primary outcomes occurred, 295 patients (7.8%) died from all-cause death, 128 (3.4%) died from cardiovascular causes, and 94 (2.5%) experienced heart failure during a median follow-up of 1,892 days. In addition, we found that higher plasma levels of OPG were associated with a higher incidence of all-cause death, cardiovascular death, and heart failure, even after adjusting clinical cofounders.

Conclusion: It was demonstrated that elevated plasma OPG levels were associated with an increased incidence of all-cause death, cardiovascular death, and heart failure in patients with stable CAD.

Systematic Review Registration: https://clinicaltrials.gov/ct2/show/NCT00000558?term=NCT00000558&draw=2&rank=1, identifier: NCT00000558.

Citing Articles

Temporal changes in biomarker levels and their association with the early degeneration stage of transcatheter aortic valves in F-fluorodeoxyglucose and F-sodium fluoride positron emission tomography studies.

Sorysz D, Dziewierz A, Gawlik K, Opalinska M, Sowa Staszczak A, Grochowska A Postepy Kardiol Interwencyjnej. 2024; 20(3):329-337.

PMID: 39464587 PMC: 11506396. DOI: 10.5114/aic.2024.142403.

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease.

Akhtar S, Ali A, Fareed A, Hasan J Health Sci Rep. 2024; 7(7):e2253.

PMID: 39044846 PMC: 11262997. DOI: 10.1002/hsr2.2253.

Serum levels of soluble receptor activator for nuclear factor kB ligand play a crucial role in the association of osteoprotegerin with coronary artery disease.

Zhou S, Wen H, Wang B, Guan S, Fang X Exp Ther Med. 2024; 28(2):325.

PMID: 38979019 PMC: 11229391. DOI: 10.3892/etm.2024.12614.

Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study.

Suh S, Oh T, Choi H, Kim C, Bae E, Ma S Sci Rep. 2024; 14(1):4136.

PMID: 38374135 PMC: 10876961. DOI: 10.1038/s41598-024-54335-y.

References

Ozkalayci F, Gulmez O, Ugur-Altun B, Pandi-Perumal S, Altun A . The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox. Balkan Med J. 2018; 35(3):225-232. PMC: 5981118. DOI: 10.4274/balkanmedj.2018.0579. View

Malyankar U, Scatena M, Suchland K, Yun T, Clark E, Giachelli C . Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000; 275(28):20959-62. DOI: 10.1074/jbc.C000290200. View

Reid P, Holen I . Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2008; 88(1):1-17. DOI: 10.1016/j.ejcb.2008.06.004. View

Omland T, Drazner M, Ueland T, Abedin M, Murphy S, Aukrust P . Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007; 49(6):1392-8. DOI: 10.1161/HYPERTENSIONAHA.107.087742. View

Bjerre M . Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus. 2013; 2:658. PMC: 3863400. DOI: 10.1186/2193-1801-2-658. View

Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S . Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology. 2012; 123(1):31-8. DOI: 10.1159/000339880. View

Braunwald E, Domanski M, Fowler S, Geller N, Gersh B, Hsia J . Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351(20):2058-68. PMC: 2556374. DOI: 10.1056/NEJMoa042739. View

Bennett B, Scatena M, Kirk E, Rattazzi M, Varon R, Averill M . Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26(9):2117-24. DOI: 10.1161/01.ATV.0000236428.91125.e6. View

Hofbauer L, Shui C, Riggs B, Dunstan C, Spelsberg T, OBrien T . Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001; 280(1):334-9. DOI: 10.1006/bbrc.2000.4130. View

10.

Knudsen S, Foss C, Poulsen P, Andersen N, Mogensen C, Rasmussen L . Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003; 149(1):39-42. DOI: 10.1530/eje.0.1490039. View

11.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

12.

Corallini F, Rimondi E, Secchiero P . TRAIL and osteoprotegerin: a role in endothelial physiopathology?. Front Biosci. 2007; 13:135-47. DOI: 10.2741/2665. View

13.

Wang Y, Liu Y, Huang Z, Chen X, Zhang B . The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov. 2022; 8(1):252. PMC: 9076607. DOI: 10.1038/s41420-022-01042-0. View

14.

Erkol A, Oduncu V, Pala S, Kizilirmak F, Kilicgedik A, Yilmaz F . Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction. Atherosclerosis. 2012; 221(1):254-9. DOI: 10.1016/j.atherosclerosis.2011.12.031. View

15.

Montagnana M, Lippi G, Danese E, Guidi G . The role of osteoprotegerin in cardiovascular disease. Ann Med. 2012; 45(3):254-64. DOI: 10.3109/07853890.2012.727019. View

16.

Secchiero P, Corallini F, Beltrami A, Ceconi C, Bonasia V, Di Chiara A . An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis. 2009; 210(1):274-7. DOI: 10.1016/j.atherosclerosis.2009.11.005. View

17.

Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K . Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost. 2010; 8(6):1170-5. DOI: 10.1111/j.1538-7836.2010.03833.x. View

18.

Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T . Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004; 44(10):1970-6. DOI: 10.1016/j.jacc.2004.06.076. View

19.

Roysland R, Bonaca M, Omland T, Sabatine M, Murphy S, Scirica B . Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012; 98(10):786-91. PMC: 3341671. DOI: 10.1136/heartjnl-2011-301260. View

20.

Shin J, Shin Y, Chung C . Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care. 2006; 29(7):1664-6. DOI: 10.2337/dc06-0631. View